Japan's Public Television Films Louisiana's LifeSource Cryobank To Feature In
Article Date: 15 Feb 2010
NHK Global Media Services, Inc., Japan's only public broadcasting television network visited Covington, Louisiana to film, LifeSource Cryobank, LLC. LifeSource will be featured in a documentary series on regenerative medicine to be aired next month in Japan.
LifeSource Cryobank is the first private company in the United States to offer both umbilical cord blood banking and adult bone marrow stem cell storage for therapeutic uses in either reparative or regenerative medicine.
"It's exciting to see Japan has a keen interest in the progress of regenerative medicine here in the United States," stated LifeSource founder and medical director, Gabriel Lasala, MD. "The producers' primary interest is in what we are doing with adult stem cells. The company's ability to aspirate a patient's own bone marrow, separate specific adult stem cells, multiply the cells in the company's GMP laboratory, and cryopreserve them for future therapeutic uses are being featured in the documentary."
The specific type of adult stem cells the company cryopreserves is called Mesenchymal Stem Cells (MSC). This adult stem cell type has the ability to repair or regenerate muscles, blood vessels, organs, and bone. The future of MSCs therapeutic treatments are extensive related to cardiovascular, nervous, skeletal and muscular systems.
"Your stem cells decrease as you age," stated Scientific Director and Cell Biologist Jose Minguell, PhD. "Harvesting your cells when you are young and storing them for the future is important."
Federal Drug Administration (FDA) clinical trials are underway to prove the safety and efficacy of MSCs usage in numerous therapies. In Covington alone, TCA Cellular Therapy is currently undergoing six FDA clinical trials using a patient's own MSCs to treat cardiovascular and neurological diseases. Two of the trials are entering Phase III, the final stage before marketability.
"The future of medicine is in adult stem cell therapy," added Dr. Lasala. "Research is moving expeditiously. Scientists anticipate FDA-approved therapeutic treatments available to the United States market as early as 2012."
Source
LifeSource Cryobank, LLC
Article Date: 15 Feb 2010
NHK Global Media Services, Inc., Japan's only public broadcasting television network visited Covington, Louisiana to film, LifeSource Cryobank, LLC. LifeSource will be featured in a documentary series on regenerative medicine to be aired next month in Japan.
LifeSource Cryobank is the first private company in the United States to offer both umbilical cord blood banking and adult bone marrow stem cell storage for therapeutic uses in either reparative or regenerative medicine.
"It's exciting to see Japan has a keen interest in the progress of regenerative medicine here in the United States," stated LifeSource founder and medical director, Gabriel Lasala, MD. "The producers' primary interest is in what we are doing with adult stem cells. The company's ability to aspirate a patient's own bone marrow, separate specific adult stem cells, multiply the cells in the company's GMP laboratory, and cryopreserve them for future therapeutic uses are being featured in the documentary."
The specific type of adult stem cells the company cryopreserves is called Mesenchymal Stem Cells (MSC). This adult stem cell type has the ability to repair or regenerate muscles, blood vessels, organs, and bone. The future of MSCs therapeutic treatments are extensive related to cardiovascular, nervous, skeletal and muscular systems.
"Your stem cells decrease as you age," stated Scientific Director and Cell Biologist Jose Minguell, PhD. "Harvesting your cells when you are young and storing them for the future is important."
Federal Drug Administration (FDA) clinical trials are underway to prove the safety and efficacy of MSCs usage in numerous therapies. In Covington alone, TCA Cellular Therapy is currently undergoing six FDA clinical trials using a patient's own MSCs to treat cardiovascular and neurological diseases. Two of the trials are entering Phase III, the final stage before marketability.
"The future of medicine is in adult stem cell therapy," added Dr. Lasala. "Research is moving expeditiously. Scientists anticipate FDA-approved therapeutic treatments available to the United States market as early as 2012."
Source
LifeSource Cryobank, LLC